France is large, sophisticated, and routinely underestimated by companies that have already “done Europe.” The UK playbook does not survive contact with French access. The US playbook does not survive contact with French promotion. This is a practical checklist for life-sciences teams who are early, not a substitute for French counsel, a local medical signatory, or a health-economist who has filed before.
I do this work as Elliogen: independent advice on market entry and commercial navigation. The point of a checklist is to know which conversations you are missing.
1. Decide what “entry” means
“We are launching in France” can mean any of:
- A legal entity and a hired general manager
- A distributor or co-promotion partner
- A named-patient / early-access posture while the full file matures
- A medical presence only (trials, KOL work) with commercial still offshore
- A digital product sold to French teams from abroad
Those are different companies. They have different cost, different pharmacovigilance and promotional exposure, and different stories you can tell HQ. Pick one for the next 18 months. “All of the above, sequenced later” is how you spend a year in workshops.
2. Access is not a localisation of the German or UK file
If you need reimbursed uptake, you are in a French process with French institutions, timelines, and evidence habits. HAS (including the Transparency Committee for medicines), pricing discussions, and hospital versus retail dynamics are not a translation layer on an EMA approval.
Questions to answer in writing, early:
- What is the plausible path to funding — and what happens if it is slower than the UK?
- What evidence will be asked for that you do not have yet (quality of life, comparative data, French real-world use)?
- Who is the economic buyer in practice (hospital, community, insurer-adjacent mechanisms)?
- Are you selling a medicine, a device, a digital tool, or a service? The doors are not the same.
If nobody in the room has sat through a French access conversation before, hire that before you hire a slogan.
3. Presence: affiliate vs partner vs “we will fly in”
A light presence is valid. A pretend presence is not. French HCPs, patient organisations, and authorities can tell the difference between a country lead who lives there and a rotating cast of HQ visitors.
Trade-offs I see:
- Affiliate — control, cost, hiring, and you own the promotional and PV operating model.
- Partner — speed and local knowledge; you inherit their reputation and their bandwidth. Your brand may never be the one in the room.
- Fly-in — fine for exploration, lethal as a permanent commercial model in a relationship market.
Write down who can sign what. Ambiguity here becomes a promotional incident or a deal that dies in legal.
4. Promotion and information are not a US website with a country picker
Medicines information and promotion in France have their own rules, own agencies, and own intolerance for copy-paste. If your global site makes claims that would not survive local review, a .fr toggle does not save you.
Practical moves:
- Inventory every URL, leave-piece, congress activity, and “non-promo” medical item that a French HCP can see
- Separate genuine medical information from brand campaigns as if a critic will screenshot both
- Do not assume English-language global content is invisible
- If you already run a claim-to-evidence discipline for the UK (see PMCPA materials), reuse the habit, not the claims
I built PromoPack for UK packs. France is not the same code. The habit of extracting claims before design still applies.
5. Patient organisations are not a UK charity with better food
French patient associations matter, and they are not interchangeable with US or UK groups of the same disease name. Mapping who is real, who is Paris-only, who will work with industry, and who will not, is local work.
Do not parachute a global “advocacy KOL” into a French plan and call it engagement. If you need the landscape, that is the same problem PatientGroups.co exists for — still do the local reading.
6. Regulatory monitoring is not “we get the EMA emails”
ANSM activity, HAS publications, and French-language safety or usage communications will not always arrive via the same inbox as FDA.gov. If your regulatory intelligence is US-centric, France will surprise you.
RegulatoryAlerts is the productised version of that watch. Even without software: name a person, name the sources, name the cadence. “Someone will see it” is not a process.
7. Hiring order is a strategy choice
A common expensive sequence: hire a sales lead, then discover access is two years away, then hire medical, then discover the materials cannot be used, then hire a consultant to unwind it.
A cheaper sequence for many first entries:
- Access and medical reality check (can this product be used, said, and paid for?)
- Legal wrapper and PV / quality minimums for the chosen presence
- A country lead who can operate that model
- Then capacity (field, marketing, more medical)
Your sequence may differ. Write one. The wrong first hire is a burn rate with a LinkedIn title.
8. What software can and cannot do
Software can watch agencies, map organisations, extract unmet needs from public conversation, and keep a claims trail tidy. It cannot sit in a HAS discussion or tell you whether a particular partner is trustworthy.
I ship the first category. Elliogen is the second. If you only need a tool, start from the products. If you need a plan for France, start at elliogen.com or book a call.